SGCB and Hepatic fibrosis: NO resistance has also been reported in resistance arteries from diabetes type II patients, hypercholesterolemic rabbits and hypertensive rats.[38] Other potential applications of sGC stimulators/activators such as the treatment of liver fibrosis, pulmonary hypertension and prevention of ischemia-reperfusion injury are currently under investigation.[26, 40, 41]